CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Clozapine +1 moredrug
Likely dose
Clozapine 550mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00498550
NCT00498550Phase 4Completed
CompareCT.gov

Cannabis and Schizophrenia: Effects of Clozapine

Dartmouth-Hitchcock Medical Center·interventional·Posted Jul 10, 2007·Updated Mar 13, 2019

In Brief

A Phase 4 clinical trial evaluating Clozapine and Treatment as usual for Schizophrenia and 4 related conditions. Completed, enrolled 31 participants across 4 sites.

Detailed Summary

Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for marijuana addiction. The purpose of this study is to compare the effectiveness of clozapine, vs. treatment-as-usual with other oral antipsychotics at reducing marijuana use in schizophrenic individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), University of Missouri, Kansas City, VA Medical Center-West Los Angeles, University of South Carolina

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 10, 2007
Enrollment StartOct 1, 2000
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 19.0 years ago

Interventions

Clozapinedrug

Clozapine up to 550mg per day

Treatment as usualdrug

Remain on pre-study antipsychotic treatment